Scholarlink

Background <p>Depression affects up to 30% of older adults and is associated with increased morbidity and mortality. Animal-assisted interventions (AAIs) - usually known as “pet therapy” - have emerged as promising complementary approaches, yet evidence synthesis remains fragmented.</p> Objective <p>To comprehensively evaluate the effectiveness of AAI in reducing depressive symptoms among older adults through an umbrella review of systematic reviews and meta-analyses, incorporating trial sequential analysis.</p> Methods <p>We systematically searched PubMed, Embase, and Cochrane Library through September 2025 for systematic reviews and meta-analyses examining AAIs for depression in older adults. Quality assessment was performed using AMSTAR-2. We calculated the Corrected Covered Area to assess overlap between meta-analyses, re-analyzed primary study data to avoid double-counting, and conducted trial sequential analysis to evaluate evidence sufficiency.</p> Results <p>Five systematic reviews encompassing 27 unique primary studies with 2,156 participants were included. The pooled random-effects meta-analysis demonstrated a significant reduction in depressive symptoms (SMD = 0.73; 95% CI: 0.57–0.89; <i>p</i> &lt; 0.001) with moderate heterogeneity (I² = 43.4%). Trial sequential analysis revealed that the cumulative Z-curve crossed monitoring boundaries at 75% of the required information size, confirming evidence sufficiency. The Corrected Covered Area was 20.4%, indicating moderate overlap between meta-analyses.</p> Conclusions <p>AAIs are associated with clinically meaningful reductions in depressive symptoms among older adults. Trial sequential analysis confirms that sufficient evidence exists to support this conclusion. AAIs represent a valuable, low-risk, patient-centered complement to conventional depression treatments in geriatric care.</p> PROSPERO registration <p>[CRD420251250448]</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Animal-assisted interventions for depression in older adults: an umbrella review with meta-analysis and trial sequential analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Marina De Rui,
  • Alessandro Perencin,
  • Mario Virgilio Papa,
  • Lisa Doria,
  • Adele Ravelli,
  • Chiara Ceolin,
  • Andrea Ungar,
  • Giuseppe Sergi,
  • Maria Devita

摘要

Background

Depression affects up to 30% of older adults and is associated with increased morbidity and mortality. Animal-assisted interventions (AAIs) - usually known as “pet therapy” - have emerged as promising complementary approaches, yet evidence synthesis remains fragmented.

Objective

To comprehensively evaluate the effectiveness of AAI in reducing depressive symptoms among older adults through an umbrella review of systematic reviews and meta-analyses, incorporating trial sequential analysis.

Methods

We systematically searched PubMed, Embase, and Cochrane Library through September 2025 for systematic reviews and meta-analyses examining AAIs for depression in older adults. Quality assessment was performed using AMSTAR-2. We calculated the Corrected Covered Area to assess overlap between meta-analyses, re-analyzed primary study data to avoid double-counting, and conducted trial sequential analysis to evaluate evidence sufficiency.

Results

Five systematic reviews encompassing 27 unique primary studies with 2,156 participants were included. The pooled random-effects meta-analysis demonstrated a significant reduction in depressive symptoms (SMD = 0.73; 95% CI: 0.57–0.89; p < 0.001) with moderate heterogeneity (I² = 43.4%). Trial sequential analysis revealed that the cumulative Z-curve crossed monitoring boundaries at 75% of the required information size, confirming evidence sufficiency. The Corrected Covered Area was 20.4%, indicating moderate overlap between meta-analyses.

Conclusions

AAIs are associated with clinically meaningful reductions in depressive symptoms among older adults. Trial sequential analysis confirms that sufficient evidence exists to support this conclusion. AAIs represent a valuable, low-risk, patient-centered complement to conventional depression treatments in geriatric care.

PROSPERO registration

[CRD420251250448]